NCT07121413View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Idiopathic Pulmonary Fibrosis(IPF)
Interventions
DRUG

SV001

SV001 ： Multiple-dose

DRUG

Placebo

Placebo ： Multiple-dose

Trial Locations (1)

Unknown

Huadong Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

Shanghai Synvida Biotechnology Co.,Ltd.

INDUSTRY